FDA cites Center for Immunology Science for a clinical trial of heat-killed Mycobacterium smegmatis without an Investigational New Drug application.
What happened
FDA inspected the company as sponsor of Protocol CISMX-001/CISMX-001B between October 7 and November 20, 2024. FDA found the company started and ran the study without submitting an Investigational New Drug application (IND) and having it in effect, and 200 human subjects received the investigational drug. The company said it thought an IND was not needed because the product was a dietary supplement, but FDA concluded it was studied as a drug to treat or mitigate immune-deficiency diseases.
What FDA found
The company began a clinical study of heat-killed Mycobacterium smegmatis in 200 people without first submitting an Investigational New Drug application (IND) and having it in effect.
21 CFR 312.20(a), 312.20(b), 312.40(a); FD&C Act ยง505 [21 U.S.C. 355]
What FDA wants
FDA asks the company to respond in writing within 15 business days with the actions it has taken to prevent similar violations and with enough detail about its corrective and preventive action plan for following IND rules.
Who should pay attention
- sponsors of clinical trials involving dietary supplements
- investigators and IRBs reviewing supplement studies
- companies planning studies of immune-related claims
This is a summary. Read the original letter on fda.gov.